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Maternal Mortality: We Must do Better
The leading causes of maternal death are thrombo-
embolism and pregnancy-induced hypertension, fol-
lowed by early pregnancy loss, hemorrhage, amniotic
fluid embolism (AFE), and genital tract sepsis [1,2]. The
goal of Healthy People 2000 was 3.3 maternal deaths/
100,000 live births [1,3]. However, little progress has
been made toward this goal worldwide. The maternal
mortality ratio has remained stable at 7.5/100,000
since 1982 (US Centers for Disease Control), but
maternal mortality is underreported in 30–60% of
investigated cases [3]. To reduce pregnancy-related
mortality, we must understand which deaths are
potentially preventable and the changes needed to
prevent them. Most deaths due to hemorrhage and
complications of chronic diseases are believed to be
potentially preventable, whereas deaths due to AFE,
microangiopathic hemolytic syndrome, and cerebro-
vascular accident are not considered preventable
[3,4]. Improved quality of medical care is considered
the most important factor in preventing these deaths.
However, approximately half of malpractice suits in
obstetrics appear to function more like a lottery than
SUMMARY
A perfect baby is the expectation of all parents, and a perfect outcome is the mission of obstetrics. Every
obstetrician dreads to hear that there is an unexpected maternal mortality and/or severe fetal injury at the
hospital. The role of a perceived public expectation of perfection in obstetric medicine reflects a belief that
bad outcomes in obstetrics should not be tolerated and that every maternal–fetal injury merits financial
compensation and punishment. What has brought these troubling times to obstetric medicine? The drivers
behind malpractice crises are the four leading interest groups in the medical-legal debate: pregnant patients
and their environment (husband, parents, relatives, friends, legislators, and the media), health-care providers,
insurance companies, and trial attorneys. Litigation in obstetrics is the result of a complex of events when
malpractice (presumed or real) impacts on the attitude of pregnant women and their environment. In such
complexity, information is mandatory but may often be misinterpreted. If messages are not tailored to the
receiver’s capacity, communicating well with the pregnant patient becomes crucial. Therefore, to reduce medical-
legal issues in obstetrics, increasing attention and an applicable standard of obstetric care to avoid negligence
and medical errors should go along with better communication with pregnant women. Communication should
be clear, targeted, effective, flexible, and empathic to share a common language and decisions. This review
briefly presents and discusses some of the most frequently encountered medical-legal claim cases in obstetric
practice. In-depth review of pregnancy-related deaths and major morbidities can help determine strategies
needed to continue making pregnancy safer. [Taiwanese J Obstet Gynecol 2006;45(1):1–9]
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as a mechanism for either quality assurance or just
retribution.
Pulmonary Embolism
Case
A 31-year-old woman, gravida 3, para 2, went into a
local clinic to deliver her third child. She had had two
previous cesarean deliveries. A repeated cesarean sec-
tion was carried out smoothly. The infant did well, as
did the mother for the first 24 hours. Unfortunately,
the woman suddenly collapsed after standing up at
08:30 the next morning, and was hypotensive and
hypoxic. She quickly became asystolic and was
immediately transferred to a tertiary medical center for
further intensive care. On admission, laboratory data
showed that acute myocardial infarction troponin-T
test was negative, creatine kinase-myocardial bound
(CK-MB) was 17 U/L (normal, < 16 U/L), and ammonia
level was 214 μg/dl (normal 0–70). Blood gas analysis
reported a pH of 6.829, base excess (BE) of –22.4
mmol/L, and oxygen saturation of 59.2%. Autopsy
suggested a possible pathophysiologic mechanism of
sudden death due to pulmonary embolism (PE).
However, inherited or acquired thrombophilia disorders
had not been investigated very thoroughly in this victim.
Comment
PE is a leading cause of maternal death, surpassing
preeclampsia–eclampsia, hemorrhage, and infection
in recent years [1,2]. Undiagnosed PE has a mortality
rate as high as 30%, which falls to near 0.7% if the
condition is diagnosed and treated appropriately. Spiral
computed tomography offers the most cost-effective
method for diagnosing this potentially fatal condition
[5]. Since the key to surviving PE is early diagnosis and
prompt treatment, in the pregnant or postpartum patient
with sudden onset of cardiorespiratory distress in whom
a clear diagnosis is not afforded by examination of the
basic parameters, therapy for the most serious diagnos-
tic possibilities, such as PE, should generally be instituted
while investigations progress. Obstetricians must be
alert to the presence of an incipient PE and aggressive in
the use of diagnostic tests and treatment. This may
mean beginning heparin or tissue plasminogen activator
therapy when conservative management with heparin
fails. There may be a place for other treatment options
including embolectomy and localized catheter-directed
thrombolytic therapy in the treatment of severe, life-
threatening PE [6–8]. Inherited or acquired thrombo-
philia should be assessed to determine the exact cause
of PE.
Inherited thrombophilia is a genetic condition that
increases the risk of thromboembolic disease, recurrent
fetal loss, fetal growth restriction, stillbirth, severe
preeclampsia, and abruptio placentae. Clinical fea-
tures are venous thrombosis occurring at a young age
and significant family history. The first venous throm-
boembolic event (VTE) is frequently precipitated by
pregnancy. The main causes are deficiencies of anti-
thrombin (incidence 1:600–1,500), protein C (1:500),
and protein S, activated protein C resistance (factor V
Leiden mutation, 5–15% of Europeans but rare in Asian
populations), factor II gene (prothrombin G20210A)
mutation (2–3% of white Europeans), and hyperhomo-
cysteinemia (mutant of ethylenetetrahydrofolate
reductase occurring in 11% of white Europeans) [9–14].
In contrast, acquired thrombophilia occurs in patients
who have antiphospholipid syndrome and lupus
anticoagulant and also among patients with essential
thrombocythemia.
In light of the rapid advances in this area, it is certain
that new causes for genetic susceptibility to venous
thrombosis in pregnancy will be identified in the near
future.
HELLP Syndrome: the Great Masquerader
or Imitator
Case
On November 17, 2003, a 34-year-old nulliparous
woman was admitted to a regional hospital to deliver
her first child. Antenatal care including blood pressure
measurements was unremarkable except a 1+ protein-
uria on urine dipstick test at 36 weeks. The labor course
was smooth, and she delivered a healthy 2,780-g infant
at 0713. After delivery, the patient experienced nausea
and epigastric pain at 09:00. Medications were provided
but in vain. Sudden onset of nausea with vomiting and
disorientation of consciousness occurred at noon. She
was immediately transferred to a tertiary medical center
for further intensive care. On admission, laboratory
data were: alanine aminotransferase (ALT) 1,020 IU/L,
lactate dehydrogenase (LDH) 3,032 IU/L, and plate-
lets 47,000/mm3. The patient’s condition deteriorated
rapidly despite intensive medical care. On the following
day, the glutamate-pyruvate transaminase level had
increased to 5,065 IU/L and LDH had climbed to 9,182
IU/L. The patient’s family requested discharge because
of her near-death status due to multisystemic organ
failure. This case is medicolegally closed because the
lawyers of both parties have reached settlement by
mediation outside the law court. The victim’s heirs were
awarded approximately NT $2,000,000 no-fault com-
pensation on moral grounds.
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Comment
Hemolysis, elevated liver enzymes, and low platelet
count (HELLP) syndrome is a unique syndrome of preg-
nancy that can be a challenge to diagnose because
the signs and symptoms of preeclampsia may appear
late in its disease course or not at all, and because the
presentation can resemble other disorders. Many pa-
tients do not, in fact, have hypertension [15,16]. The
lowest platelet count and the peak ALT and LDH values
occur within 72–96 hours after delivery. The presence of
nausea with or without vomiting, right upper-quadrant
or epigastric pain, or both in association with exces-
sive laboratory values including LDH (> 1,400 U/L),
ALT (> 150 IU/L), uric acid (> 7.8 mg/dL), serum creati-
nine (> 1.0 mg/dL), and 4+ urinary protein can be used
to identify the patient at high risk for significant ma-
ternal morbidity [17]. An ALT of more than 2,000 IU/L,
LDH above 3,000 IU/L, or presence of hypoglycemia
is the major marker for maternal death [15,16]. The
normal time course for resolution of laboratory ab-
normalities is about 4 days, and delayed recovery needs
to be evaluated for additional causes.
A recent Cochrane review on the subject concluded
that there is insufficient evidence to determine whether
adjunctive corticosteroid use in women with HELLP
syndrome decreases major morbidity [18,19]. However,
experimental antepartum and/or postpartum high-dose
corticosteroid therapy (> 24 mg/day; 10 mg dexa-
methasone iv q6h for 2 doses followed by 6 mg q6h
for 2–4 doses) and/or plasma exchange may be life-
saving approaches in selected cases without single or
multiple organ injuries [20–23]. Although HELLP syn-
drome takes an indolent course, in some patients, the
disease may progress with astonishing and frighten-
ing rapidity and culminate in maternal death. In re-
viewing all the records of patients who died from HELLP
syndrome, Weinstein found that the most common
family of drugs that all patients had received in the days
before death was not an antihypertensive or magnesium
sulfate but an antacid for “heartburn” [15]. HELLP
syndrome could be considered “gastrointestinal
preeclampsia.” [15,24]. Therefore, if a patient complains
of heartburn, epigastric or right upper-quadrant pain,
clinical and laboratory evaluations are warranted.
Currently, much research is evaluating the immuno-
logic basis for the disease, but little progress in clinical
management has ensued. Delay in diagnosis is associ-
ated with mortal consequences. The cure for preeclamp-
sia will remain elusive but we need to improve early
recognition, close medical supervision, safe prolonga-
tion of pregnancy, and timely induction of labor when
necessary. We hope this case presentation can alert
other health-care providers to the serious nature of
this disease so that proper medical treatment can be
offered, thus avoiding morbidity and death.
Amniotic Fluid Embolism
In AFE, the obstetrician is a scapegoat, i.e. “one who
bears the blame for unexpected, unavoidable, un-
predictable, unpreventable and unacceptable tragic
misfortunes of (placenta–fetus) foreign antigen–
antibody-mediated anaphylactic reaction”. In some
cases, unfortunately, despite our best intentions, pa-
tients die, and the clinicians involved often become the
“secondary victims”.
Case
Hsieh et al reported the case of a 34-year-old woman,
gravida 7, para 3, who went to hospital to deliver her
fourth child [25]. Four hours after admission, the pa-
tient experienced a sudden intrapartum episode of
respiratory distress, cyanosis, and disorientation of
consciousness. An emergency cesarean delivery was
performed. Cardiorespiratory resuscitation was per-
formed because of acute circulatory and respiratory
collapse. Arteriovenous extracorporeal membrane
oxygenation (ECMO) and intra-aortic balloon counter-
pulsation procedures were instituted after the cesarean
delivery and maintained 40 hours postpartum. The pa-
tient was discharged after 24 days of hospitalization.
Amniotic fluid elements were observed in the blood
from the central vein. In addition, another case has
recently come to light with sudden onset of AFE during
preoperative preparation for elective cesarean delivery
because of placenta previa at term. At the time of
writing this article, the patient is still in a vegetative
state despite aggressive ECMO support after this no-
fault tragic event.
Comment
AFE appears to be initiated after maternal intravascular
exposure to fetal and/or placental materials contained
in amniotic fluid (which itself appears to be nontoxic),
and anaphylactic reaction plays a role in the pathophysio-
logy of AFE [25–28]. Mediators including amniotic fluid
contents, plasma components, pulmonary endothe-
lium, and leukocytes (mast cells) are responsible for the
anaphylactic reaction of AFE. The chronology of symp-
toms and signs of AFE can be divided into three phases.
The first phase has three predominant manifestations:
respiratory distress and cyanosis; hypotension, pulmo-
nary edema, and shock; and seizures or coma. The
second phase includes coagulopathy and hemorrhage,
while the third phase includes multisystemic organ
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injury. All these occur during labor or cesarean delivery
or 30 minutes after vaginal delivery with no other
explanation for the findings. For confirmation of AFE,
fetal constituents, for example, fetal squames, lanugo,
vernix caseosa, mucin, or bile granules, must be found
in the maternal lung. It is important to identify the
responsible antigen and mediators, if possible. Mast
cell degranulation products include histamine, which
peaks in 10 minutes and has a half-life of 2 minutes, and
tryptase, which, in contrast, peaks 1–2 hours after the
inciting event and has a half-life of 2 hours. Thus, tryp-
tase has proved to be a better laboratory marker for
anaphylaxis than histamine [27]. The more difficult
task of searching for specific immunoglobulin E to fetal
proteins could rely on polyacrylamide gel electrophore-
sis and Western blot techniques [27]. The obstetrician
must send blood samples from a wedged catheter to
the laboratory to confirm the clinical diagnosis when
unexpected AFE occurs during labor or delivery. This
procedure is important in a setting where the manifesta-
tions of AFE closely resemble that of PE.
Pharmacologic treatment includes inotropics and
hydrocortisone 500 mg intravenously (iv) every 6 hours.
In addition, rapid and aggressive plasma therapy re-
places consumed coagulation factors and inhibitors,
and also presumably supplied angiotensin-converting
enzyme, aminopeptidase P, and carboxypeptidase N,
which quickly inactivate bradykinin. The rapid clearance
of vasodilatory kinins probably contributes to preventing
the extravascular leakage that is usually observed in
AFE [28]. The last resort of life-saving treatment is to
use ECMO and intra-aortic balloon counterpulsation.
Anaphylactic reactions induced by AFE may be transient
and resolve within a few hours. Cardiopulmonary by-
pass plays a major role in saving the lives of patients by
providing a few critical hours to maintain the cardio-
vascular status of AFE victims [25].
Placenta Percreta
An in vitro fertilization case with antenatal undiag-
nosed placenta percreta causing uterine rupture with
fatal hemoperitoneum at 23 weeks of gestation has
been reported [29]. An approximately NT$ 750,000
settlement was reached through mediation in 1986.
In contrast, a victim of placenta percreta with bladder
involvement underwent emergency total abdominal
hysterectomy and partial cystectomy because of pre-
mature rupture of membranes and antepartum
hemorrhage at 19 weeks of gestation. The patient was
awarded no-fault compensation with the hospital
paying NT$ 2,180,000 for her psychosocial suffering
from urinary system sequelae (2004, lawbank website).
Additionally, we are aware of a case of maternal
death due to massive hemorrhage after vaginal delivery
in a local clinic. In-depth review of the cause of death by
autopsy revealed that placenta accreta was responsible.
However, in an astonishing case, a patient with pla-
centa previa percreta and bladder involvement survived
after two major surgical procedures and massive blood
transfusions at 39 weeks of gestation despite total esti-
mated blood loss of 47,000 mL [29]. These case reports
raise concern that the danger of bleeding from placenta
previa accreta is very obvious. Therefore, “fire drills” are
necessary to practice a protocol for the management of
massive intrapartum and postpartum hemorrhage in
every maternity unit, and it is recommended that the
most experienced obstetrician must be available under
these circumstances.
An allegation of failure to diagnose placenta accreta
is a relatively common cause of medical negligence
claims against general practitioners. Therefore, every
obstetrician should be aware of the efficacy, limitation,
and pitfalls of current imaging techniques in diagnosing
placenta accreta [29–31]. Early antepartum identifi-
cation of placenta accreta/increta/percreta offers oppor-
tunity for termination of life-threatening pregnancy or
alteration in the surgical approach to achieve a planned
delivery with the use of pelvic artery balloon occlusion
techniques in viable late pregnancy and/or internal iliac
artery embolization for non-viable pregnancy in the
first and early second trimesters, thus diminishing blood
loss, morbidity, and mortality [32]. First-trimester
diagnosis should therefore be pursued aggressively in
any woman with placenta previa and an at-risk history
of previous uterine surgery [29,33,34].
Uterine Rupture
Case
A 39-year-old woman, gravida 6, para 5, was transferred
to a tertiary medical center because of postpartum he-
morrhage. She had a significant history of three success-
ful vaginal births after cesarean deliveries (VBAC). On
December 29, 2003, the patient experienced shoulder
dystocia (head–body interval delivery time > 30 minutes,
infant weight 4,450 g), and neonatal death occurred
during her fourth attempt at VBAC at 40 weeks of gesta-
tion in a local hospital. The patient underwent emer-
gency laparotomy that revealed hemoperitoneum and
lower uterine segment rupture. Total abdominal hyste-
rectomy was performed, followed by postoperative pel-
vic angiographic embolization due to intraoperative
difficulty in achieving satisfactory deep pelvic hemosta-
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sis. The patient was admitted to the intensive care unit
(ICU) for further care, and discharged in a stable con-
dition. The attending obstetrician was not sued for mal-
practice negligence.
Comment
A trial of labor after prior cesarean delivery is associ-
ated with a greater perinatal risk than elective repeated
cesarean delivery without labor, although absolute risks
are low. A rate of uterine rupture of 6.2/1,000 trials of
labor (880 uterine ruptures in 142,075 trials of labor)
has been reported [35]. Risk factors for uterine rupture
are increased maternal age, history of two previous
cesarean deliveries, postpartum fever after the previ-
ous cesarean delivery, short interdelivery interval,
and a history of classical incision [36–38]. Therefore,
clinicians should be particularly careful in patients with
prior cesarean section or a weakened uterus. The rate
of uterine rupture related to VBAC is 2.4% in pro-
staglandin (PG)-induced labor, in comparison with
0.4–0.52% in nonaugmented, spontaneous labor and
0.77–1.0% in patients receiving oxytocin augmentation
[39]. Therefore, the risk of uterine rupture during VBAC
attempts is substantially increased with the use of
various prostaglandins, and they should be used with
caution. Aslan et al reported a higher rate of uterine
rupture (9.7%) in patients undergoing a trial of labor
with a history of previous cesarean delivery in which
labor was induced with misoprostol [40]. In contrast,
accidental uterine rupture of an unscarred uterus fol-
lowing labor induction with misoprostol occurs in 0.1–
1% and only rare cases have been attributed to the use
of misoprostol. There is a concern about the use of
approved drugs for unlabeled indications. Prescribing a
Food and Drug Administration (FDA)-approved drug
for an indication that does not have FDA sanction often
causes concern and confusion among practitioners.
The FDA Drug Bulletin 1982;12(1) states: ‘Once a product
has been approved for marketing, a physician may
prescribe it for use or in treatment regimens or patient
populations that are not included in approved labeling.
Such “unapproved” (unlabeled) uses may be appropri-
ate and rational in certain circumstances, and may, in
fact, reflect approaches to drug therapy that have been
extensively reported in medical literature.’
Cardiotocography is of limited or no value for silent
uterine rupture, which is difficult to diagnose. Warning
signals are often absent and the rupture is clinically
suspected only after it has occurred. The classic des-
cription of a decrease in uterine tone or the cessation of
labor at the time of uterine rupture has been refuted
by intrauterine pressure monitoring data. The most
common single warning signal is an abnormal fetal
heart rate pattern. Ultrasonographic measurement of
a lower uterine segment thickness of more than 2.0–
3.5 mm has an excellent negative predictive value for the
risk of uterine defect [41].
A standardized cesarean technique should be used
to avoid the potential severe consequences of uterine
rupture, cesarean scar pregnancy, and invasive placent-
ation in subsequent pregnancies. Opening the uterus
with a knife, the operator makes a small transverse
incision in the appropriate mid-portion of the uterine
muscle (the level of the incision depends upon the
level of the head and should be as near as practicable to
the widest diameter) and cuts down to the amniotic
membrane, extending the incision laterally by means of
curved scissors. A final enlargement can be made by
blunt expansion using index fingers into the uterine
incision and stretching it from side to side. We do not
recommend making the whole width of the uterine
aperture by crude tearing, which tends to leave ragged
margins, rather than a regular square edge that allows
accurate repair. When stitching the uterus, care is taken
to avoid the uterine decidua. It is most important to use
continuous running sutures and maintain good tension
with appropriate insertion and accurate placing of the
inner row of sutures (ensuring that the shaggy margins
of the decidua are not interposed between the muscle
tissues), followed by a second layer with wide mus-
cular bite closure. If the decidua has not been carefully
excluded, a gutter runs along the scar on its inner mu-
cosal surface. This constitutes a permanent weakness
and, in a subsequent pregnancy, favors the occurrence
of a hernia of the membrane, which gradually protrudes
through the wall. That is the usual manner in which the
uterus ruptures in a subsequent pregnancy when labor
occurs. In addition, if in a subsequent pregnancy the
placenta implants over the scar, the destructive action
of the chorionic villi on the fibrous tissue becomes
pronounced and very decidedly predisposes to cesarean
scar pregnancy and/or placenta accreta.
Maternal Death Due to Septic Shock after
Second-Trimester Genetic Amniocentesis
We are aware of at least three maternal deaths caused
by septic shock after genetic amniocentesis in Taiwan.
Accordingly, we report a recent case of ultimately fatal
maternal sepsis caused by chorioamnionitis-associated
septic shock in a twin pregnancy after mid-trimester
genetic amniocentesis.
Case
A patient, who had undergone amniocentesis 2 days
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before presentation at a local hospital because of twin
pregnancy with an abnormal maternal serum test at 18
weeks of gestation, was referred to a tertiary medical
center due to febrile morbidity (39°C). At that time, she
had a white blood cell (WBC) count of 17,500/mm3,
a C-reactive protein (CRP) of 3.4, and a urine routine
WBC 3+ with bacteria. She was empirically given iv
cefazolin 1 g 6 hourly, gentamycin 80 mg 8 hourly, and
metronidazole 250 mg 8 hourly after consultation with
the infectious diseases physician.
The patient was transferred to the ICU because of
worsening respiratory distress caused by pulmonary
edema. She delivered two stillborn fetuses weighing
230 and 200 g, respectively. Unfortunately, postpartum
hemorrhage developed after uterine curettage for re-
tained placenta. There was a rapid decompensation
in both the clinical and laboratory status (CRP 20.5,
WBC 24,100/mm3) consistent with septic shock and
disseminated intravascular coagulopathy. Sudden onset
of ventricular tachycardia was followed by asystole, and
the patient died despite aggressive cardiorespiratory
resuscitation. Biopsy of the placenta revealed acute
chorioamnionitis. Bacterial culture from the placenta
specimen grew coagulase-negative staphylococci, and
no bacteria grew from all other blood cultures, urine
culture, and cervix culture. The exact etiology of the
sepsis in this case is unclear since autopsy was not per-
formed. The temporal relationship between the amnio-
centesis procedure and the maternal/fetal death sug-
gests the possibility of an association. This case was
medicolegally closed because the lawyers of the three
parties reached a settlement by mediation outside the
law court. The victim’s heirs were awarded approximately
NT$ 2,800,000 no-fault compensation on moral
grounds.
Comment
It is generally accepted that severe complications are
underreported [42]. Obstetric care providers and genetic
counselors should be aware of potential serious mater-
nal morbidity and mortality that may occur after a
needle is inserted into the gravid uterus, and any patient
complaints thereafter should be regarded seriously
[43]. The incidence of chorioamnionitis is 3.7/1,000
cases after amniocentesis. Infection is usually mild to
moderate. There are, however, rare sporadic reports in
the literature describing cases of postamniocentesis
sepsis with devastating results [43–45]. Review of the
literature revealed 10 more cases of sepsis after trans-
abdominal genetic amniocentesis. Contamination of
the uterine cavity after prenatal genetic diagnostic pro-
cedures may occur through ascending infection from
the patient’s endogenous vaginal flora, direct inocula-
tion of intestinal germs due to inadvertent intestinal
penetration, and, rarely, after use of deficiently sterilized
equipment. The principal pathogens responsible for
septic shock in obstetric patients are Escherichia coli,
Clostridium spp, Bacteroides spp, Klebsiella–Enterobacter–
Serratia group, Proteus spp, and Pseudomonas aeruginosa.
Other pathogens are atypical organisms such as Gram-
positive aerobic bacteria and Gram-negative anaerobic
bacteria.
Most obstetric patients with bacteremia respond
promptly to iv antibiotic therapy. In isolated instances,
however, the patient may develop the life-threatening
complication of septic shock, which has an alarmingly
high mortality rate. Mabie and Barton reported 18
patients with septic shock in pregnancy. The causes of
shock were pyelonephritis (6), chorioamnionitis (3),
postpartum endometritis (2), toxic shock (2), and one
each of septic abortion, ruptured appendix, ruptured
ovarian abscess, necrotizing fascitis, and bacterial
endocarditis [46].
The management of the gravid patient with septic
shock due to chorioamnionitis presents a particularly
difficult problem for the obstetrician [47]. Sepsis after
prenatal diagnosis can be devastating. Postamnio-
centesis chorioamnionitis is usually managed with
antibiotics and termination of pregnancy, if necessary
to prevent maternal sepsis and related morbidity and
mortality. Management strategy suggests that antibiotic
treatment and expectancy may be an option in selected
cases of postamniocentesis chorioamnionitis in multiple
pregnancies. Surgery in the presence of deteriorating
maternal vascular function is clearly hazardous. It may
be necessary, however, precisely because surgical re-
moval of the focus of infection is the only way to
stabilize the critically ill patient. Although immediate
evacuation of the uterus by dilatation or by hystero-
tomy may be considered, these aggressive efforts did
not prevent maternal death in three reported cases in
the literature [43–45]. In rare cases, simple evacuation
of the uterine content is insufficient. However, the
decision to perform a hysterectomy is difficult, especially
in the case of a young nulliparous woman. Moreover,
the condition develops so rapidly that it does not always
allow time for a proper diagnostic work-up and pre-
paration of the patient.
The most effective treatment for maternal sepsis is
prevention. Preventive measures that may be employed
in the pre-amniocentesis period include stabilization
of the patient’s preexisting medical disease, sterile
amniocentesis pack, aseptic skin care, aseptic placement
of the amniocentesis needle, and prophylactic antibio-
tic treatment in selected patients. The obstetrician’s
attention should be directed primarily towards early
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identification of patients with infection-related com-
plications. Appropriate informed consent for genetic
amniocentesis should include an additional statement
such as: “rarely there may be severe maternal compli-
cations from amniocentesis related to infection and/or
sepsis, even if the proper precautions are taken” [43].
Shoulder Dystocia
Case
A 34-year-old woman, gravida 2, para 1, had gestational
diabetes mellitus controlled by diet. Her membranes
ruptured at 06:40, and she was admitted to the hospital
at 38 weeks of gestation. Unfortunately, a shoulder
dystocia occurred (head–body delivery time about 2
minutes) after the fetal head was delivered at 13:38.
The first stage of labor was 1 hour 30 minutes, and the
second stage lasted only 8 minutes. The shoulder dystocia
may have been caused by failure to allow the natural
molding of the baby’s shoulders to the contours of
the birth canal because of the short second stage and
chest-to-head disproportion in the diabetic woman.
The Apgar scores were 4, 7, and 8 at 1, 5, and 10
minutes, respectively. The baby weighed 3,824 g. The
infant had suffered an evulsive brachial plexus injury
due to shoulder dystocia, resulting in persistent Erb’s
palsy in the right arm at the age of 12 months. A lawsuit
was filed on the child’s behalf, and the case had not
been settled at the time of writing.
Comment
Shoulder dystocia is one of the obstetrician’s greatest
fears, and the most dreadful complication because of
five “U” characteristics: unexpected, unpredictable,
unpreventable, unavoidable, and unacceptable [48].
Most cases cannot be predicted or prevented because
there are no accurate methods for identifying which
fetuses will develop this complication. Ultrasound mea-
surements for estimating macrosomia have limited
accuracy. The absolute error of estimated fetal weight
(EFW) formulas ranges from 7% to 10% within 1 week
of delivery, and may be as high as 15% [49]. Thus, when
calculated on a 4,000-g infant, the margin of error
is 600 g. Planned cesarean deliveries on the basis of
suspected macrosomia are not a reasonable strategy
[50]. However, planned cesarean section may be rea-
sonable for the nondiabetic woman with an estimated
fetal body weight of more than 4,500 g or for the
diabetic woman at more than 4,000 g.
Recently, Mehta et al reported their findings in a
unique article demonstrating that errors in EFW, and
specifically underestimation of EFW, are not associated
with an increased risk of shoulder dystocia [49]. This is
especially important given the number of lawsuits
involving shoulder dystocia cases. We are aware of a
victim of shoulder dystocia with brachial plexus injury
awarded no-fault compensation of NT$ 2,800,000
because of suspected deviation from the standard of
care due to underestimation of EFW (EFW 3,100 g, act-
ual birth weight 4,136 g) and inappropriate maneuvers
to deliver this macrosomic infant (March 11, 2004,
lawbank website).
Shoulder dystocia followed by permanent brachial
plexus injury or mental impairment is one of the leading
causes of malpractice allegations. Erb’s palsy (C5–C7)
is a paralysis of shoulder and arm muscles resulting in
a hanging upper arm that may be extended at the el-
bow. Duchenne palsy (C7–T1) is a palsy including the
hand (clawhand deformity). Most brachial plexus in-
juries are transient and recover completely by 13 months,
although 5–22% become permanent.
In the typical brachial plexus case, plaintiffs always
claim that the birth attendant must have exerted exces-
sive lateral traction on the infant’s neck during delivery
for a permanent injury to have occurred. However, there
is solid evidence for the possibility of an in utero injury
and that maternal endogenous factors, namely uterine
expulsive force and maternal pushing, can cause injury.
Furthermore, Dr. Raymond Jennet observed that bra-
chial plexus injuries do occur in the absence of shoulder
dystocia during vaginal deliveries [51,52].
The obstetrician should call for help and follow all
management rules when shoulder dystocia occurs. The
standard obstetrical maneuvers used for its relief
must be well rehearsed. The most popular techniques
include: McRobert’s maneuver and suprapubic pres-
sure, followed by Woods corkscrew maneuver or deli-
very of the posterior shoulder, then, in order, Rubin
maneuver, Zavanelli maneuver, abdominal rescue (after
failed cephalic replacement), symphysiotomy, and frac-
ture of the clavicle or cleidotomy. Prompt assessment
and management of shoulder dystocia and preparation
to maximize the efficiency of shoulder dystocia maneu-
vers are critical. Documentation of the appropriate use
of maneuvers to relieve shoulder dystocia demonstrates
standard of care practice, thereby decreasing the poten-
tial for successful malpractice allegations [51].
In conclusion, most obstetricians will potentially be
sued if they practice long enough. Similarly, exhortations
for birth attendants to become either more educated
or more sensitive are unlikely to reduce almost half of
these pregnancy-related deaths, which are potentially
unpreventable. Therefore, the obstetrician has become
an endangered species in the era of medical-legal claims,
fault and no-fault financial compensation, unaffordable
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medical liability awards and increasing professional
liability premiums, and injustice of National Health
Insurance. We as a society must get on with the hard,
time-consuming task of medical injury compensation
act legislation and develop a more rational and fair
system of medical jurisprudence [53]. Otherwise, the
pattern of obstetricians reducing their obstetric practice
or discontinuing obstetric practice entirely will continue
and medical students will no longer be interested in
pursuing the profession that we all love. Until then, who
will deliver our grandchildren [53,54].
Addendum
Often, the factual information available about the
medical-legal closed cases presented here is incomplete.
Thus, it may not always be possible to discuss all of the
elements of negligence or nuances involved in a given
situation. The outcomes described may not reflect the
current standard of care or the best practice in obstet-
rics. What these cases do represent are the types of
clinical situations in maternal–fetal medicine that typi-
cally result in litigation. We hope that some of the cases
described have merit.
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